Equity Strategy
29 March 2023
Our Roadmap for the Next 12 Months
Drawing a roadmap using CY19
 

In a macro context, we see many similarities between 2019 and our outlook for 2023, although with some key differences. Given these parallels, we believe using parts of 2019 as a potential playbook for our equity strategy in the current year is appropriate.

Figure 2: Our 2023 views vs 2019
Our Macro View 2023 2019 Events
Slowing economic growth. Global growth and PMIs slowed over the course of 2019.
Close to the end of rate hikes. In 2019 the US Fed started to cut rates after a period of hiking in 2018.
Bond yields continuing to trend lower. AU and US 10 year bond yields fell in 2019 as the Fed and RBA cut rates.

Source: Refinitiv, Wilsons.

Similarities to 2019

Growth concerns followed by a slowdown

In 2018, equities had a weak end due to concerns about the global economy. While the reasons for global growth concerns differ, they remain persistent factors driving equity markets in 2022 and 2023.

The global economy slowed in 2019, but no downturn eventuated. In a similar vein, our base case remains that the US and domestic economy can avoid a recession, but a slowdown appears likely.

Figure 3: PMIs indicate growth concerns; just as they did in 2019
Figure 4: Fed funds and cash rate futures are implying cuts in H2FY23

Central banks cutting?

The US Fed and RBA cut rates in 2019 after economic growth slowed.

While the motives for cuts this year will be different, the market is now pricing cuts to the Fed and RBA after a fall in confidence in the global banking system.

In comparison to genuine "crisis" periods such as the COVID dislocation of 2020 and the GFC, our analysis suggests most market stress indicators are still a long way from "extreme" levels. Therefore, while cutting in the latter part of this year or next year seems likely, we don't think it will be due to a sharp downturn like during the pandemic or the GFC.

We currently view the market as too aggressive with its cutting profile. However, we believe some easing later in 2023 (for the Fed) and late 2023 or early 2024 (for the RBA) is plausible.

Figure 5: The RBA and US Fed cut rates in 2019; bonds continued to fall during the cuts

Bond yields have scope to fall further

Bonds tend to preempt falls in the Fed funds rate and RBA cash rate, but cutting rates typically leads to further declines in bond yields. This was the case in 2019, and 2023 may be similar.

 

What Sectors Performed in 2019

In 2019 the best sectors were:

  • Non-cyclical growth – Tech and healthcare performed well as bond yields fell.
  • Cyclical growth – Media, consumer discretionary and financial services performed well as bond yields fell and the economic outlook improved.
  • Materials performed well as China-US relations concerns faded. Gold also performed well after the Fed pivoted and heightened uncertainty.
Figure 6: Growth and defensive sectors performed the best in 2019; banks had a tough year

Banks had a tough 2019, with slower economic growth, lower interest rates and some idiosyncratic issues (the Royal Commission's fallout still impacting sentiment).

Positioning Towards Growth, With a Preference to Non-Cyclical Growth

One of our key portfolio overweights is to growth, with a preference for non-cyclical growth such as healthcare, tech and stocks like IDP Education (IEL) and Lotteries Corporation (TLC). We see these stocks, like in 2019, to be key beneficiaries of lower rates/bond yields and a slowdown in economic growth.

Cyclical growth stocks should also benefit from a valuation perspective and an improving outlook on certain aspects of the economy if rates fall.

Nine Entertainment (NEC) should benefit from lower rates and improving housing market sentiment owing to its 60% ownership of online housing classified Domain (DHG). Macquarie (MQG) and James Hardie (JHX) will likely rerate when rates fall, while earnings prospects would improve on investment banking and US housing respectively.

Figure 7: We are positioned towards growth sectors, with a preference to non-cyclical growth
 

There Are Some Differences

  • Rates hikes in 2022 were more extreme than Fed hikes in 2018.
  • The RBA did not tighten in 2018.
  • Inflation backdrop is very different relative to 2018/19.
  • Even after cuts, rates will likely remain high relative to the lows in 2019.
  • Persistent inflation is still a risk to the rate cut scenario.
  • Tail risk event probabilities are heightened in 2023 vs 2019 due to the fast pace of monetary tightening.
  • China reopening in 2023 could be a key support for global GDP.

In Light of These Differences, How Are We Safeguarded?

Recession risk mitigation

We hold stocks in the portfolio that should provide downside protection if the worst was to happen. Although our preference is for defensive growth stocks, these should provide a shield against a worsening outlook.

Persistent inflation risk

We believe the best defence against persistent cost inflation is pricing power. High quality companies with resilient customer demand through the cycle and dominant market positions operating in attractive industry structures are best placed to protect their margins by raising prices.

China reopening

We have increased our exposure to the China reopening by adding IDP Education (IEL) at the beginning of the month, with Chinese students providing a tailwind for earnings growth over the next 12 months. We also hold Goodman Group (GMG) and Qantas (QAN), who should benefit from the increased economic activity in China and domestically.

 

Healthcare Stocks Cover a Number of Scenarios

We think healthcare gives us protection in many different scenarios, hence it is our biggest overweight in the portfolio.

We think the sector performs well if:

  • Bond yields continue to fall (which should happen in a slowdown or a recession) – supporting valuations.
  • Economy slows or goes into a recession – earnings should hold up in this scenario (fewer downgrades than cyclicals).
  • Pricing power protects against inflation (if more persistent than expected).

Our key healthcare names are CSL (CSL), ResMed (RMD) and Telix (TLX).

  • Share This Article

Written by

Rob Crookston, Equity Strategist

Rob is an experienced research analyst with a background in both equity strategy and macroeconomics. He has a strong knowledge of equity strategy, asset allocation, and financial and econometric modelling.

Disclaimer and Disclosures

About Wilsons Advisory: Wilsons Advisory is a financial advisory firm focused on delivering strategic and investment advice for people with ambition – whether they be a private investor, corporate, fund manager or global institution. Its client-first, whole of firm approach allows Wilsons Advisory to partner with clients for the long-term and provide the wide range of financial and advisory services they may require throughout their financial future. Wilsons Advisory is staff-owned and has offices across Australia.

Disclaimer: This communication has been prepared by Wilsons Advisory and Stockbroking Limited (ACN 010 529 665; AFSL 238375) and/or Wilsons Corporate Finance Limited (ACN 057 547 323; AFSL 238383) (collectively “Wilsons Advisory”). It is being supplied to you solely for your information and no action should be taken on the basis of or in reliance on this communication. To the extent that any information prepared by Wilsons Advisory contains a financial product advice, it is general advice only and has been prepared by Wilsons Advisory without reference to your objectives, financial situation or needs. You should consider the appropriateness of the advice in light of your own objectives, financial situation and needs before following or relying on the advice. You should also obtain a copy of, and consider, any relevant disclosure document before making any decision to acquire or dispose of a financial product. Wilsons Advisory's Financial Services Guide is available at wilsonsadvisory.com.au/disclosures.

All investments carry risk. Different investment strategies can carry different levels of risk, depending on the assets that make up that strategy. The value of investments and the level of returns will vary. Future returns may differ from past returns and past performance is not a reliable guide to future performance. On that basis, any advice should not be relied on to make any investment decisions without first consulting with your financial adviser. If you do not currently have an adviser, please contact us and we would be happy to connect you with a Wilsons Advisory representative.

To the extent that any specific documents or products are referred to, please also ensure that you obtain the relevant disclosure documents such as Product Disclosure Statement(s), Prospectus(es) and Investment Program(s) before considering any related investments.

Wilsons Advisory and their associates may have received and may continue to receive fees from any company or companies referred to in this communication (the “Companies”) in relation to corporate advisory, underwriting or other professional investment services. Please see relevant Wilsons Advisory disclosures at www.wilsonsadvisory.com.au/disclosures.

Related articles